Novartis M&A Strategy Under Fire as Trial Setbacks Shake Investor Confidence

What happened

Novartis investors are stepping up scrutiny of the company's M&A strategy after trial setbacks involving acquired drugs, which have hit the share price and raised concerns about pipeline quality. The company had recently completed bolt-on acquisitions such as Anthos and Myricx to deepen its oncology and specialty pipelines, while also facing the ongoing Entresto patent cliff and a premium valuation. H1 2026 results already showed operating income down 6% and margin compression to 32.6%, with net debt rising to $39.4 billion after $11.7 billion in acquisition spending. The new trial setbacks add execution risk to the acquired assets, questioning whether the M&A-driven pipeline can deliver the growth needed to offset legacy declines. This narrative shift from simple patent-cliff replacement to proof of value from both internal and acquired programs makes the next 6-9 months even more decisive for the stock.

Implication

Investors should treat this M&A scrutiny as an additional headwind for the stock's premium multiple. The company's net debt has risen significantly, and failed acquisitions could lead to impairments or further pressure on free cash flow. Positive H2 2026 catalysts (Pluvicto approval, pelacarsen, remibrutinib, del-desiran) are now even more necessary to restore confidence. If these readouts disappoint alongside M&A setbacks, the stock could fall toward the bear case of $128. Conversely, successful pipeline validation would mitigate concerns, but the current uncertainty argues for patience.

Thesis delta

The WAIT rating is unchanged, but the risk profile has skewed further to the downside. Investor scrutiny of M&A outcomes heightens the need for positive pipeline readouts to offset both Entresto erosion and potential acquisition write-downs. The balance sheet is more leveraged after recent deals, reducing margin of safety if acquired assets underperform.